Three murine major histocompatibility complex (MHC) class II-restricted T cell determinants were identified in the major capsid protein L1 of human papillomavirus (HPV) type 16. Peptides derived from HPV-16 L1, which contain putative T cell epitopes located by a predictive algorithm, were synthesized and tested for lymphoproliferative activity by direct immunization, followed by in vitro assay of responses to peptides or recombinant HPV-16 L1. The MHC restriction of the stimulatory peptides was determined using blocking monoclonal antibodies against class II molecules. The responses, which were specific for the priming peptides alone, cross-reacted with recombinant L1 but not with analogous peptides derived from other HPV types.
Introduction
Human papillomaviruses (HPVs) are small DNA viruses which infect the cutaneous epithelium and the mucosa to produce a variety of clinically different proliferative tumours. On the basis of DNA homology there are currently around 60 types of HPV described (de Villiers, 1989) . Of interest is the marked segregation of different HPV types between clinically different lesions. There is now increasing evidence that certain HPV types are associated with premalignant and malignant diseases of the genital tract. HPV-6 and HPV-11 are found most commonly in cervical condylomata, benign lesions which tend to regress spontaneously, and low grade cervical intraepithelial neoplasia (CIN). High grade CIN lesions and malignancies are usually associated with HPV-16 and HPV-18, types which occur very rarely in condylomata zur Hausen & Schneider, 1987) . Despite this close link, the precise role of HPV in malignant transformation remains unclear.
Approaches for the successful prevention or treatment of HPV infection by immunological means such as vaccination require a thorough understanding of the immunobiology of this virus. Presently there is no direct information available on the relative importance of cellmediated and humoral responses in the control of infection. Cell-mediated immunity is implied by studies which clearly demonstrate a balance between a competent cellular immune response and HPV infection. 
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For instance, reduced cellular immunocompetence is frequently associated with the development of warts or condylomata (Brodersen et al., 1974; Morison, 1975a, b; Chretien et al., 1978; Lutzner et aL, 1983) , whereas spontaneously regressing warts feature lymphoid cell infiltration (Tagami et al., 1985; Iwatsuki et al., 1986; Thivolet et al., 1982) . Less is known about the humoral response. Despite demonstrations of HPV-specific immunoglobulins (Ig) in human sera and cervical secretions (reviewed by Galloway & Jenison, 1990) , their role in protection remains open to debate. In the main, our understanding of the immune reactions elicited by HPV, the cells and cytokines involved and how they correlate with the development or regression of lesions remains unclear.
Progress in the area of HPV immunology requires the identification of viral proteins and the areas within them recognized by both T and B lymphocytes. The purpose of this study, which forms part of a larger study of the immunology of HPV using both human and murine systems, was to identify and characterize murine helper T (Th) cell epitopes of HPV. Immunization of mice with predefined antigen obviates problems associated with human studies where cross-reactive responses caused by unknown prior infections may occur. Our studies have focused initially on the late open reading frame (ORF) L1, which encodes the major capsid protein of HPV-16. Obtaining sufficient quantities of native L1 protein for immunological study is presently difficult owing to the absence of an in vitro culture system for the virus. Therefore we located putative T cell epitopes within the primary amino acid sequence of L1 protein using a predictive algorithm (Rothbard & Taylor, 1988 ) and synthetic peptides containing predicted determinants were then used as immunogens to generate class IIrestricted Th cells. In addition we have produced recombinant L1 protein in Escherichia coli as a nonfusion protein. In proliferation assays, peptide-primed T cells responded specifically to the priming peptides and also to preparations of recombinant HPV-16 L1 protein adsorbed to nitrocellulose. However, peptides from the L1 molecules of other HPV types were found not to stimulate primary cultures of HPV-16-primed T cells.
A parallel study using the same peptides with human Th cells (Strang et al., 1990) , in which cells responded to identical peptides as did the murine cells, indicates that the murine system can complement human studies by enabling relevant responses to defined papillomavirus (PV)-derived immunogens to be tested directly by immunization. The definition of these T cell determinants is important for stringent diagnostic identification of HPV in infections and in the rational design of subunit vaccines to HPV.
Methods
Choice of peptides, synthesis, analysis and purification. Peptides chosen for synthesis were selected from determinants detected in the primary amino acid sequence of HPV-16 L1 (Seedorf et al., 1985) using a predictive algorithm (Rothbard & Taylor, 1988) based on sequences common to T cell epitopes. Analogues to these determinants were identified within the L1 molecules of HPV types la, 5, 6b, 8, 11, 18 and 33 (Danos et al., 1982; Zachow et al., 1987; Schwarz et al., 1983; Fuchs et al., 1986; Dartmann et al., 1986; Cole & Danos, 1987; Cole & Streek, 1986 ) by a multiple sequence alignment program (Taylor, 1988) . Peptides were synthesized using solid phase techniques (Barany & Merrifield, 1979) on an Applied Biosystems Peptide Synthesizer with commercially available reagents (Applied Biosystems). The peptides were cleaved from the resin and the side-chain-protecting groups were simultaneously removed with anhydrous hydrofluoric acid with anisole as a free radical trap. The side-chain-protecting groups were extracted with ether. Subsequently, the peptides were dissolved in 15% acetic acid, filtered from the resin and lyophilized. The crude peptides were analysed by HPLC on a C-8 reversed phase column (Aquapore RP-300, Brownlee Laboratories) and by amino acid analysis. Peptides that were not of greater than 90% purity as judged by analytical HPLC analysis were purified by using a preparative RP-300 column and a water-trifluoroacetic acid-acetonitrile gradient. Principal peaks were collected, lyophilized and analysed by amino acid analysis.
Recombinant proteins. The plasmid pJ4~ 16L 1, which was generously provided by Neil Almond (National Institute for Biological Standards and Controls, Potters Bar, U.K.) and Lionel Crawford (ICRF Tumour Virology Group, University of Cambridge, Cambridge, U.K.), was used as the source of HPV-16 LI DNA. This construct contains an AfllII fragment of HPV-16 isolated from the HPV-carrying keratinocyte line W12 (Stanley et al., 1989) , to which NcoI and BgllI linkers were sequentially coupled prior to ligation into the BgllI site of plasmid pJ4fl. This fragment (nucleotides 5592 to 7265) contains all but the first 33 bp of the HPV-16 L10RF (nucleotides 5559 to 7153). To produce a recombinant non-fusion L1 protein, the excised and blunt-ended NcoI fragment from pJ4~ql6Ll was ligated into the SmaI cloning site of the bacterial expression vector pKK223.3 (Pharmacia) to give pKKL1.1. A similar construct was produced by the addition of HindlII linkers to the BgllI fragment cut from pJ4D16L1, followed by its ligation into the HindIII site of pKK223.3; this construct was termed pKKL1.2. Colonies of transformed E. coli strain JM105 were then expanded in 5 ml mini-cultures in Luria-Bertani (LB) medium, induced for 1 h with 2 x 10 -s M-isopropyl fl-D-thiogalactoside (IPTG) and screened for expression by Western blotting using standard methods (Burnette, 1981) with a panel of monoclonal and polyclonal antibodies (see Antibodies below). Construct pKKL1.1 expressed a product of the expected Mr of 57K and pKKL1.2 a major degradation product of 30K (see Results). Two additional constructs supplied by H. zur Hausen (German Cancer Research Centre, Heidelberg, F.R.G.) were also used. In these, a DdeI fragment o1" HPV-16 (nucleotides 5692 to 7761) was cleaved with EcoRI and fragments 5692 to 6818 and 6819 to 7761 were cloned separately into the temperature-inducible vector pPLC24 (Remaut et al., 1981) to generate constructs MS2L1/I/2 and MS2L1/23/2, respectively. These express truncated HPV-16 L1 proteins fused at the N terminus to the first 98 amino acids of bacteriophage MS2 replicase. Transformed E. coli strain 537 was grown at 28 °C until it reached the stationary phase, diluted 1:4 with LB medium and induced at 42 °C for 3 to 5 h.
In lieu of purified recombinant L1, a colloidal suspension of nitrocellulose/L1 particles was prepared for use as antigen in proliferation assays. Induced bacteria were dissolved in half a volume of SDS-PAGE sample buffer (Laemmli, 1970) , 2 ml of which was applied to a 150 x 3 mm stacking gel trough, and subjected to electrophoresis through a 10~ acrylamide gel. After transfer for 18 h at 250 mA to nitrocellulose (Schleicher & Schuell), the vertical end strips were removed and stained with the monoclonal antibody (MAb) Camvir-I (McLean et al., 1990) to reveal L1 and the L1 band was then excised from the unstained remainder of the blot. Negative controls for all four recombinant L1 proteins were proteins of appropriate Mr derived from E. coil JM105 transformed with plasmid pKK233.3 alone (without L1 insert) and blotted onto nitrocellulose; positive controls were particles derived from nitrocellulose incubated in 10mg/ml peptides. The nitrocellulose strips were transformed into particles by solubilization in DMSO (5 ml/cm 2) and precipitation by dialysis against phosphate-buffered saline (PBS), followed by extensive washing in PBS.
Antibodies. For screening of E. coli for expression of HPV-16 L1 by Western blotting, the following Ll-specific antibodies were used. MAbs Camvir-1 (raised against HPV-16 L1 residues 198 to 531 fused to fl-galactosidase; McLean et al., 1990) , 1D6, 8C4, 5A4 and 3D1 (all raised against HPV-16 L1 residues 207 to 409 fused to fl-galactosidase; Patel et al., 1989) and two rabbit polyclonal antisera, one raised to a 14 amino acid peptide (HPV-16 L1 C-terminal residues 517 to 531 ; Banks et aL, 1987) and the other to disrupted bovine papillomavirus type 1 virions (Dako). For immunostaining, hybridoma supernatants were diluted to 1/10 and polyclonal antisera to 1/100 in blocking buffer (2 casein in Tris-buffered saline pH 7.4) and visualized with peroxidaseconjugated anti-mouse or anti-rabbit sera (Dakopatts) used at 1/1000 in blocking buffer.
The major histocompatibility complex (MHC) restriction of proliferating T cells from H-2 k (CBA) and H-2 d (B10D2 and BALB/c) mice was determined by blocking proliferation of primary lymph node cells with filter-sterilized, purified IgG fractions of culture supernatants of hybridomas 14.4.4S (anti-I-Ek/d), HB3 (anti I-A d) and H40 (anti I-Ak). In the proliferation assay (see below), the peptide concentration was maintained at 15 ~tM and the antibodies were used at 10-fold serial dilutions of 50 p.g/ml.
Proliferation assay. (CBA x BALB/c) F1 mice (haplotype H-2kxd), and both corresponding parental strains, were primed subcutaneously at the base of the tail with 25 lag soluble peptide or PBS emulsified in complete Freund's adjuvant (CFA) (Difco). Draining lymph node cells, pooled from three to five mice, were challenged 8 days later in vitro for specific proliferation to the priming peptide, or to truncated forms of it, analogous peptides from other HPV types, or recombinant L1/nitrocellulose particles. Proliferation assays wereperformed essentially as described (Corradin et al., 1977) . Cell suspensions were assayed in triplicate cultures in fiat-bottomed 96-weU plates (Falcon) at 3 x 105 cells/well in Iscove's modified Dulbecco's medium (Gibco) with 5~ foetal calf serum (FCS), supplements (Chain et al., 1987) and serial dilutions of appropriate antigen. When truncated peptides were used as the challenge antigens, the peptides were adjusted to molar equivalents to enable quantitative comparisons to be made between proliferative responses. Particles were tested in threefold serial dilutions of 10 mmZ/ nitrocellulose well. Proliferation was determined by incorporation of [3H]thymidine (1 gCi/well) during the final 6 h of a 3 day culture period, followed by liquid scintillation counting of harvested DNA.
Results

Identification of murine T cell determinants of HPV-16 L1
Eight peptides from the HPV-16 L10RF containing potential T cell determinants were synthesized (Fig. 1) . These peptides all contain the four or five residue predictive motif described by Rothbard & Taylor (1988) . The length of the peptides was chosen such that a motif of four amino acids is flanked by six residues on either side, whereas a motif of five is flanked by five residues. This guarantees that all possible decamers contained within the peptide will contain the motif.
Initially, (CBA x BALB/c) F1 mice were immunized individually with 25 ~tg of each peptide and lymph node cells were assayed for specific proliferation to the immunizing peptide; three peptides caused proliferative responses (Fig. 2) . The relative responses of these is 40 to 63 greater than 91to 106 which in turn was greater than 279 to 294. No significant response by the F1 mice was observed to the remaining five peptides. Typically, the response increased to a maximum with increased concentrations of peptide in the assay. Occasionally, at higher concentrations of peptide, decreases in response were observed. Responses were shown to be specific for the priming peptide by the lack of recognition of irrelevant peptides or of the other L1 peptides (not shown). T cells primed to PBS emulsified in CFA did not respond to any of the eight peptides (not shown). In other studies the responses of (B10Br × B10D2) F1 and (CBA x DBA/2) F1 mice, which are also H-2 kxd, were identical to those of the (CBA x BALB/c) F1 hybrids (not shown).
In these initial experiments, F1 mice were immunized with individual peptides. The difference in proliferative response to the peptides administered individually ( (Fig. 3) indicate a similar hierarchy of responses (Fig. 2) when each peptide is used to immunize mice separately. To examine Ir gene control of the response, parental strains CBA and BALB/c were immunized with individual peptides. Both were responders to the same three peptides to which the F1 hybrids responded, indicating that both haplotypes are able to recognize these sequences (Fig. 2) . A moderate response to peptide 295 to 310 also was observed in CBA mice.
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Proliferation to recombinant L1
Attempts to express L1 protein from construct pKKL1.2 in E. coli yielded a degradation product of Mr 30K (Fig.   4) . Relocation of the L10RF to minimize the physical separation between its start codon (provided by the NcoI linker) and the Shine-Dalgarno sequence located upstream within the tac promoter (to give construct pKKL1.1) resulted in the expression of a full-size 57K product (Fig. 4) . Screening of expression on Western blots was performed initially with the antibody Camvir-1 (epitope mapped to residues 230 to 236; McLean et al., 1990) . Positive staining with this antibody was reproduced with antibodies 1D6, 8C4, 5A4 and 3D1 (the minimal epitope of each mapped to residues 276 to 278; Cason et al., 1989) , and also with the anti-C-terminal peptide rabbit polyclonal antiserum. The latter antiserum recognized the 57K protein but not the 30K protein (not shown). The Dako anti-BPV-1 was negative in these experiments.
To examine cross-reactivity of peptide-primed T cells to whole L1 protein, the 57K, 30K, MS2L1/1/2 and MS2L1/23/2 proteins (all bound to nitrocellulose particles) were assayed in proliferation assays. Studies with titrations of particles demonstrated a cytopathic effect that increased (i.e. T cell proliferation decreased) directly with particle concentration. A cut-off point where counts fell sharply to zero occurred at nitrocellulose concentrations of 0.3 to 1.0 mm2/well. Proliferation data for titrations of antigen particle concentrations were aligned by the cut-off point, thus enabling the proliferation by the same population of primed T cells to different particulate antigens to be compared. The results of three separate immunizations using three different batches of antigen are shown in Table 2 . Although the difference in response to L1 particles over the appropriate negative control particles was often only marginal, responses by T cells primed 'to the three immunogenic peptides were seen in different experiments. Consistency of such responses was difficult to demonstrate although responses to truncated versions of L1 (the 30K and MS2L 1/1/2 proteins) occurred more frequently than they did to the full-size protein. Responses to MS2L1/23/2 proteins were not seen. These studies indicate that the three immunogenic peptides elicit T cells that also respond to recombinant L1 proteins.
Proliferation in response to truncated peptides and identification of analogous sequences from other HP V types
Identification of stimulatory determinants was refined by assaying nested sets of truncated peptides. These peptides were tested for proliferative activity in vitro with primary lymph node cells derived from animals primed with the full-length peptide. The data are summarized in Table 3 . In H-2 ~ mice, peptide 50 to 63 is the minimum length required to stimulate 40 to 63-specific T cells. In both H-2 k and H-2 d mice, peptide 91 to 106 lost activity with any N-terminal deletion or within two C-terminal deletions. In comparison, any deletion of peptide 279 to 294 resulted in loss of activity. These minimum peptide Tables 4 and 5 and text). § ND, Not determined. (Zuckerman & Howard, 1979; Mahy, 1985; Osato et al., 1986) , indicates the likelihood ofT cell involvement in the control of HPV infection. In particular, the Th cell regulatory compartment is critical for any effective immune response. Therefore, this study is directed toward understanding the Th cell response to HPV antigens.
Owing to the present lack of an in vitro culture system for HPV, obtaining significant quantities of native HPV antigens for immunological studies is problematic but synthetic peptides and the products of recombinant DNA technology can be used as surrogate antigens. In this study a predictive template was used to locate T cell determinants within the L10RF of HPV-16. Eight synthetic peptides, each containing one or more potential determinants, were produced. In addition, we have generated a recombinant HPV-16 L1 protein which is not fused to a carrier protein. This protein exhibits reactivity on Western blots with antibodies that recognize three different epitopes in the HPV-16 L1 protein molecule. The lymphoproliferative properties of the peptides were then tested by immunization of mice with peptide followed by an in vitro proliferation assay. Three peptides from HPV-16 L1 (40 to 63, 91 to 106 and 279 to 294) elicited proliferation to the original priming peptide and to the recombinant L1 protein. No cross-reactivity occurred between primary lymph node cultures primed to HPV-16 peptides and analogue peptides from other HPV types. In most cases the differences between the HPV-16 peptides and the analogous peptides is no more than two to three amino acids, indicating that primed T cells of primary lymph node cultures exhibit a normal high degree of specificity.
In our parallel study, the HPV-16 L1 peptides used in the present study have been screened in lymphoproliferative assays using human peripheral blood lymphocytes (PBL) and lines (Strang et al., 1990) . Of the eight peptides, four were recognized by the majority of a group of individuals, although no single peptide was recognized by all donors and no donor responded to all four peptides. In the present study, it is shown that three of the four peptides were also recognized by murine haplotypes H-2 k and H-2 d. The four stimulatory peptides are (with restriction element in parentheses) 40 to 63 (DR 4 Dw4; I-Ek/d; I-Ak/d), 91 to 106 (DR 3; I-Ek/d; I-Ak), 219 to 244 (DR 4 Dw4) and 279 to 294 (DR 7; I-E TM; I-Ak). These peptides thus show permissiveness of binding both between class II restriction elements and MHC haplotypes. This apparent low degree of peptide/MHCbinding specificity has been noted in numerous in vitro and in vivo systems and may reflect multiple MHCbinding determinants within peptides, or the ability of individual peptides to assume a variety of conformations suitable for binding to multiple MHC molecules. Moreover, predictive algorithms based on a consensus sequence derived from many different antigens may preferentially select for permissiveness of this sort.
One interpretation of the proliferative responses of human PBL to the peptides (Stranget al., 1990 ) is that the responding T cells had been primed previously to HPV-16 L1 protein during natural infection. Similarly (but in reverse), the present murine study has shown that T cells primed to peptides can respond to the whole L1 molecule in proliferation assays. Although this study is not strictly analogous with the human study, identical epitopes (40 to 63, 91 to 106 and 279 to 294) were identified in both. Relevant epitopes are likely to be revealed in both immunization protocols, i.e. immunization with the whole protein (or virus) followed by stimulation in vitro with peptides, and immunization with peptides followed by stimulation With the whole protein. Improved sources of L1 protein, native or recombinant, need to be produced to describe reliably the relevant (immunodominant) Th epitopes within the HPV-16 L1 molecule.
The cros~o-reactivity between the lymphoproliferative peptides derived from HPV-16 L1 and analogous sequences within the L1 molecules of other HPV types was examined. The intention of such studies is a clearer understanding of the distribution of cross-reactive T cell epitopes. Such epitopes, by conferring immunity to multiple HPV types, are potentially beneficial. Crossreactive epitopes may reveal instances of naturally occurring immunological cross-reactivity for infections of different HPV types and may also influence the construction of synthetic subunit vaccines. However, in the present murine study, the predominant response by primary lymph node cultures was to the priming peptide alone, despite the high degree of sequence similarity of the analogue peptides to the priming antigen. In the human study (Strang et al., 1990) , we reported that some human T cell clones which respond to HPV-16 peptides also respond to a few corresponding sequences from other HPV types. However, cross-reactivity does not seem prevalent in either the murine or human systems. Thus, fragment immunogens may elicit responses confined to only a few specific HPV types. This antigenic diversity found among different HPV types may reflect the influence of strong selective pressures imposed by a successful immune response to HPV from the host. Despite the minimal cross-reactivity between HPV types, the observed permissiveness of peptide binding by MHC molecules is more encouraging for vaccine design. This phenomenon suggests that a given epitope may be an effective stimulator of populations of T cells with different M HC restriction. This is of particular relevance for an immunogen which must be effective within the diverse MHC repertoire of an outbred population.
